Zytiga, Mavyret and 161 items monitored for PVA negotiation

NHIS posts Type Ga and Na negotiating drugs for the third quarter

The South Korean health authority added Korea Otsuka Pharmaceutical’s Iclusig tablet (ponatinib hydrochloride hydrate), Jassen Korea’s Imbruvica capsule (ibrutinib), Zytiga tablet (abiraterone acetate) and Darzalex (daratumumab) as subject for the third quarter price-volume agreement (PVA) negotiation and monitoring.

 

Merck’s Erbitux injection (cetuximab), MSD Korea’s Zepatier tablet and AbbVie Korea’s Mavyret tablet are other addition to the list.

 

On its website, National Health Insurance Service (NHIS) recently posted the list of drugs to be monitored for the PVA negotiation (Type Ga and Na) during the third quarter.

 

The PVA system stipulates NHIS and pharmaceutical companies to share the NHI finance risk, and lowers pricing of a drug with surged use volume after negotiating with NHIS.

 

In the third quarter, 163 items in 89 classes would be monitored.

 

The PVA monitoring list included Sam-oh Pharm’s Vimizim injection (elosulfase alfa), Sanofi-Aventis Korea’s Mozobil injection (plerixafor), SK Plasma’s SK Albumin, and Roche Korea’s Mircera prefilled injection (methoxypolyethyleneglycol-epoetin beta).

 

Korea Otsuka Pharmaceutical’s Samsca tablet (tolvaptan spray dry powder) and Yuhan’s Prakanon tablet (pranlukast hydrate) have also been added to the list.

 

The Type Ga (가) PVA negotiation is applicable on a drug that exceeded the benefit claim amount by 30 percent over the projected claim amount set according to pricing negotiation with NHIS, projected claim negotiation, pricing increase adjustment negotiation and indication expansion negotiation.

 

The Type Na (나) PVA negotiation is applicable on a drug either completed the Type Ga negotiation or reaches annual claim amount after a year since the day the Type Ga monitoring period ended without a negotiation in four years that exceeds previous year’s claim by 60 percent or 10 percent but surpassing 5 billion won.

 

However, drugs claiming less than 1.5 billion won annually or having upper limit pricing lower than average pricing among same class drugs, low-priced drug and shortage prevention drug are exempted from the PVA negotiation.